Advertisement
U.S. markets closed
Advertisement

Isoray Inc (AAJ.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.23000.0000 (0.00%)
At close: 08:08AM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.2300
Open0.2300
Bid0.2320 x 500000
Ask0.2420 x 500000
Day's Range0.2300 - 0.2300
52 Week Range0.2080 - 0.6500
Volume0
Avg. Volume3
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AAJ.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

      Imaging was conducted as part of a clinical study at Technical University of Dresden in GermanyImage was selected as “Image of the Month” in the European Journal of Nuclear Medicine and Molecular Imaging, November 2023Radiolabeling was performed on-site using a Company-provided generator SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the publication of the first human SPECT images utilizing the alp

    • GlobeNewswire

      Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

      SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline. The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals. “The results from these preclinical studies are compelling and continue to support our ongoing clinical efforts to advance our novel lead-based target

    • GlobeNewswire

      Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy

      SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors (NETs). This milestone follows the recent completion of the first dose escalation cohort for Perspective’s melanoma therapeutic [212Pb]VMT01. “We are pleased with the progress of our Com